Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

RVTY — Revvity

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 12.35%
Profit Margins 8.26%
Return on Equity 3.23%
Return on Assets 2.27%
Free Float 0.1B
Dividend Yield 0.25%
Short Int % Utilisation 11.75%

2.2 Growth

Metric Value
Revenue Growth 7.0%
Free Cash Flow 0.51B
EBITDA 16.12 (Ratio)
Enterprise Value 13.79B
EV/Revenue 4.75
EV/EBITDA 16.12

Revenue growth of 7.0% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 39.00%
Risk / Std Dev (Ann.)* 38.14%
1-Year Price Return* 29.06%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $116.84
52-Week Range $81.22 – $118.34
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $2.86B $2.76B
Net income Reported net income $241.20M $270.38M
Total assets Year-end reported balance $12.17B $12.39B
Shareholders’ equity Year-end reported balance $7.25B $7.67B
Net margin Net income ÷ revenue 8.45% 9.81%
Asset turnover Revenue ÷ total assets 0.2347x 0.2223x
Equity multiplier Total assets ÷ shareholders’ equity 1.6783x 1.6164x
ROE Net margin × asset turnover × equity multiplier 3.33% 3.53%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $2.86B
Prior annual revenue $2.76B
EBIT $360.46M
Tax rate 10.60%
NOPAT = EBIT × (1 − tax rate) $322.25M
Forecast start-growth basis 3.67%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $322.25M
Add: depreciation & amortisation $405.34M
Less: capital expenditure -$73.52M
Less/(add): working-capital cash-flow movement -$96.78M
Current unlevered FCFF $557.29M

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 3.67% $334.07M $420.20M -$76.22M -$100.33M $577.73M $553.63M
2 3.38% $345.35M $434.39M -$167.69M -$103.72M $508.33M $447.33M
3 3.08% $355.99M $447.78M -$264.50M -$106.91M $432.36M $349.41M
4 2.79% $365.93M $460.28M -$366.08M -$109.90M $350.23M $259.92M
5 2.50% $375.08M $471.79M -$471.79M -$112.65M $262.43M $178.85M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 1.07
Cost of equity 10.61%
Pre-tax cost of debt 2.74%
WACC 8.89%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $4.21B
Implied terminal EV / EBITDA 4.72x
Terminal value as % of enterprise value 60.56%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $1.79B
Present value of terminal value $2.75B
Indicated enterprise value $4.54B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $4.54B
Less: gross interest-bearing debt $3.40B
Add: cash and equivalents $919.86M
Add: affiliate investments $0.00
Less: minority interests $0.00
Indicated common equity value $2.06B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 116,595,000.00
Share-count basis reported diluted weighted-average shares
Current market price $114.52
DCF indicative value per share $17.65
Indicative value vs. market price -84.59%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 3/4 evidenced checks
Lynch-inspired balance-and-growth checks 3/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:48:08.583676 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -3.41% 5.81%
Adjusted R² 0.32 0.36
Annualised residual volatility 32.28% 31.13%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 1.27 (6.67) 1.51 (7.15)
Size (SMB) 1.19 (4.64) 0.89 (3.34)
Value (HML) 0.13 (0.58) -0.48 (-1.82)
Profitability (RMW) NM 0.01 (0.06)
Investment (CMA) NM 1.50 (3.87)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequityrvtyhealth-carehealth-care-equipmentnasdaq